Short communication: a modified Vaccinia virus Ankara-based Porcine circovirus 2 vaccine elicits strong antibody respons
- PDF / 901,081 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 190 Views
VETERINARY MICROBIOLOGY - SHORT COMMUNICATION
Short communication: a modified Vaccinia virus Ankara-based Porcine circovirus 2 vaccine elicits strong antibody response upon prime-boost homologous immunization in a preclinical model Danielle Soares de Oliveira Daian e Silva 1 & Edel Figueiredo Barbosa-Stancioli 1 & Jordana Graziela Alves Coelho-DosReis 1 & Flávio Guimarães Da Fonseca 1 Received: 14 November 2019 / Accepted: 17 February 2020 # Sociedade Brasileira de Microbiologia 2020
Abstract Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species. Keywords Porcine circovirus 2 . Capsid protein . Modified Vaccinia virus Ankara (MVA) . Recombinant vaccine . Homologous vaccination regimen
Abbreviations PCV2 Porcine circovirus 2 CAP Capsid protein PCVAD Porcine circovirus-associated diseases PMWS Postweaning multisystemic wasting syndrome MVA Modified Vaccinia virus Ankara MVA-CAP Recombinant MVA expressing CAP
Highlights • A MVA-vectored PCV2 vaccine was designed and tested on a preclinical model. • Two homologous doses of the vaccine elicited strong antibody response. • The lyophilized vaccine was stable for up to one year when stored at 4 °C. Responsible Editor: Fernando R. Spilki. * Flávio Guimarães Da Fonseca [email protected] 1
Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG CEP: 31270-901, Brazil
Introduction Modifications of consume habits associated to possible health and economic advantages have led to an increase in the global swine farming and commercialization of pig products [1]. The constant expansion of the swine industry, especially in developed countries, has been characterized by the reduction of farm numbers and a correspondent increase in herd sizes [1]. As a result, pig farming in increasingly higher densities allows for the transmission of pathogens and the dissemination of diseases [2]. One of the most economically important pathogens for the swine industry worldwide is the Porcine circovirus 2 (PCV2), a
Data Loading...
